Ji, H. ; Englmaier, F. ; Morigny, P. ; Giroud, M. ; Gräsle, P. ; Brings, S.* ; Szendrödi, J.* ; Berriel Diaz, M. ; Plettenburg, O. ; Herzig, S. ; Rohm, M.
Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia.
Mol. Ther. 31, 2408-2421 (2023)
Cancer cachexia is a severe systemic wasting disease that negatively affects quality of life and survival in patients with cancer. To date, treating cancer cachexia is still a major unmet clinical need. We recently discovered the destabilization of the AMP-activated protein kinase (AMPK) complex in adipose tissue as a key event in cachexia-related adipose tissue dysfunction and developed an adeno-associated virus (AAV)-based approach to prevent AMPK degradation and prolong cachexia-free survival. Here, we show the development and optimization of a prototypic peptide, Pen-X-ACIP, where the AMPK-stabilizing peptide ACIP is fused to the cell-penetrating peptide moiety penetratin via a propargylic glycine linker to enable late-stage functionalization using click chemistry. Pen-X-ACIP was efficiently taken up by adipocytes, inhibited lipolysis, and restored AMPK signaling. Tissue uptake assays showed a favorable uptake profile into adipose tissue upon intraperitoneal injection. Systemic delivery of Pen-X-ACIP into tumor-bearing animals prevented the progression of cancer cachexia without affecting tumor growth and preserved body weight and adipose tissue mass with no discernable side effects in other peripheral organs, thereby achieving proof of concept. As Pen-X-ACIP also exerted its anti-lipolytic activity in human adipocytes, it now provides a promising platform for further (pre)clinical development toward a novel, first-in-class approach against cancer cachexia.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Adipose Tissue ; Ampk ; Cachexia ; Cancer ; Metabolic Dysfunction ; Peptide-drug; Activated Protein-kinase; Cell-penetrating Peptides; Body-composition; Lipolysis; Adipocytes; Phosphorylation; Transcription; Homeostasis; Metabolism; Mechanism
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2023
Prepublished im Jahr
0
HGF-Berichtsjahr
2023
ISSN (print) / ISBN
1525-0016
e-ISSN
1525-0024
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 31,
Heft: 8,
Seiten: 2408-2421
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Nature Publishing Group
Verlagsort
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
90000 - German Center for Diabetes Research
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Helmholtz Diabetes Center
Enabling and Novel Technologies
PSP-Element(e)
G-501900-257
G-501900-251
G-506300-001
G-501900-253
Förderungen
NIGMS NIH HHS
Copyright
Erfassungsdatum
2023-10-18